Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders
(2003) In Biological Chemistry 384(2). p.281-287- Abstract
- Secretory type 2 cystatins, like cystatins C, E/M and F, are thought to be involved in many pathobiological processes, including vascular amyloidosis, rheumatoid arthritis, Alzheimers disease, osteoporosis, viral and bacterial infections, inflammatory disorders and tumour invasion and metastasis. In order to define the levels of cystatins C, E/M, and F in pleural effusions and to investigate whether these cystatins correlate with diagnostic parameters of pleural and lung diseases, we determined their concentrations in 160 pleural effusions. The median concentration of cystatin C in pleural effusions was 1437 mug/l (95.8 nM), ranging between 18-3967 mug/l. Cystatin C did neither correlate with malignant nor with benign diseases. The... (More)
- Secretory type 2 cystatins, like cystatins C, E/M and F, are thought to be involved in many pathobiological processes, including vascular amyloidosis, rheumatoid arthritis, Alzheimers disease, osteoporosis, viral and bacterial infections, inflammatory disorders and tumour invasion and metastasis. In order to define the levels of cystatins C, E/M, and F in pleural effusions and to investigate whether these cystatins correlate with diagnostic parameters of pleural and lung diseases, we determined their concentrations in 160 pleural effusions. The median concentration of cystatin C in pleural effusions was 1437 mug/l (95.8 nM), ranging between 18-3967 mug/l. Cystatin C did neither correlate with malignant nor with benign diseases. The concentration of cystatin E/M was significantly higher in effusions of primary pleural tumours (mesotheliomas) compared to secondary pleural tumours and benign diseases. Furthermore, there was a significant correlation between the concentration of cystatin E/M of mesotheliomas and the pleural fluid tumour cell count and of cystatin C. The median values of cystatin F were significantly increased in parapneumonic/ empyema thoracis pleural effusions and tuberculous pleurisy compared to malignant pleural effusions, respectively. The concentration of cystatin F in benign effusions correlated significantly with diagnostic parameters and inflammation (total protein; lactate dehydrogenase; C-reactive protein). Finally, only in the group of parapneumonic/empyema thoracis was there a significant correlation between cystatin F and the neutrophil count. In conclusion, pleural effusions of different origin contain high levels of cystatin C, perhaps constituting the major part of an inhibitor reservoir. The level of cystatin E/M appears to be significantly associated with primary pleural tumours and cystatin F correlates with inflammatory processes of lung disorders. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/317951
- author
- Werle, B ; Sauckel, K ; Nathanson, Carl-Michael LU ; Bjarnadottir, M LU ; Spiess, E ; Ebert, W and Abrahamson, M LU
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- inhibitors, peptidase, mesothelioma, cysteine peptidases, lung inflammation, pleural effusion
- in
- Biological Chemistry
- volume
- 384
- issue
- 2
- pages
- 281 - 287
- publisher
- De Gruyter
- external identifiers
-
- wos:000181175000012
- pmid:12675521
- scopus:0037300636
- ISSN
- 1437-4315
- DOI
- 10.1515/BC.2003.031
- language
- English
- LU publication?
- no
- id
- 006acc66-c9cb-442f-9fa4-76881143d97a (old id 317951)
- date added to LUP
- 2016-04-01 11:38:30
- date last changed
- 2022-02-18 02:40:02
@article{006acc66-c9cb-442f-9fa4-76881143d97a,
abstract = {{Secretory type 2 cystatins, like cystatins C, E/M and F, are thought to be involved in many pathobiological processes, including vascular amyloidosis, rheumatoid arthritis, Alzheimers disease, osteoporosis, viral and bacterial infections, inflammatory disorders and tumour invasion and metastasis. In order to define the levels of cystatins C, E/M, and F in pleural effusions and to investigate whether these cystatins correlate with diagnostic parameters of pleural and lung diseases, we determined their concentrations in 160 pleural effusions. The median concentration of cystatin C in pleural effusions was 1437 mug/l (95.8 nM), ranging between 18-3967 mug/l. Cystatin C did neither correlate with malignant nor with benign diseases. The concentration of cystatin E/M was significantly higher in effusions of primary pleural tumours (mesotheliomas) compared to secondary pleural tumours and benign diseases. Furthermore, there was a significant correlation between the concentration of cystatin E/M of mesotheliomas and the pleural fluid tumour cell count and of cystatin C. The median values of cystatin F were significantly increased in parapneumonic/ empyema thoracis pleural effusions and tuberculous pleurisy compared to malignant pleural effusions, respectively. The concentration of cystatin F in benign effusions correlated significantly with diagnostic parameters and inflammation (total protein; lactate dehydrogenase; C-reactive protein). Finally, only in the group of parapneumonic/empyema thoracis was there a significant correlation between cystatin F and the neutrophil count. In conclusion, pleural effusions of different origin contain high levels of cystatin C, perhaps constituting the major part of an inhibitor reservoir. The level of cystatin E/M appears to be significantly associated with primary pleural tumours and cystatin F correlates with inflammatory processes of lung disorders.}},
author = {{Werle, B and Sauckel, K and Nathanson, Carl-Michael and Bjarnadottir, M and Spiess, E and Ebert, W and Abrahamson, M}},
issn = {{1437-4315}},
keywords = {{inhibitors; peptidase; mesothelioma; cysteine peptidases; lung inflammation; pleural effusion}},
language = {{eng}},
number = {{2}},
pages = {{281--287}},
publisher = {{De Gruyter}},
series = {{Biological Chemistry}},
title = {{Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders}},
url = {{http://dx.doi.org/10.1515/BC.2003.031}},
doi = {{10.1515/BC.2003.031}},
volume = {{384}},
year = {{2003}},
}